<DOC>
	<DOCNO>NCT01023516</DOCNO>
	<brief_summary>The primary objective evaluate efficacy AZD9668 compare placebo symptomatic COPD patient assess effect lung function symptom COPD</brief_summary>
	<brief_title>Efficacy Safety Twice Daily 60mg AZD9668 COPD 12 Weeks Patients Background Budesonide/Formoterol</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Diagnosis COPD symptom 1 year FEV1/FVC &lt; 70 % FEV1 &gt; = 30 &lt; 80 % predict postbronchodilator Symptomatic COPD total 7 day two week prior randomisation At least 1 COPD exacerbation 4 week 12 month screen visit Past history current evidence clinically significant heart disease Current diagnosis asthma Patients require long term oxygen therapy Worsening COPD require treatment antibiotic , increase inhale steroid dose and/or oral steroid within 4 week study visit 1b</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Chronic</keyword>
	<keyword>obstructive</keyword>
	<keyword>pulmonary</keyword>
	<keyword>lung</keyword>
	<keyword>respiratory disease</keyword>
	<keyword>efficacy</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>COPD</keyword>
	<keyword>FEV1</keyword>
	<keyword>St Georges Respiratory Questionnaire</keyword>
</DOC>